[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:primary-membranous-nephropathy":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":66,"states":71},"Primary Membranous Nephropathy",9,[7,15,21,27,34,41,47,53,60],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07571746","A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease",[11],"Phase 2","RECRUITING","2026-08-26T02:18:39.640967Z","2026-05-13T02:55:06.777799Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT07096843","A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy",[11],"2026-08-26T02:18:21.216897Z","2026-05-05T02:43:29.465978Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":25,"content_modified":26},"NCT07157787","Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)",[11],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:29.336655Z",{"nct_id":28,"title":29,"phases":30,"status":12,"updated_at":32,"content_modified":33},"NCT07204275","Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)",[31],"Phase 2\u002FPhase 3","2026-08-26T02:19:17.380174Z","2026-05-05T02:43:28.312957Z",{"nct_id":35,"title":36,"phases":37,"status":12,"updated_at":39,"content_modified":40},"NCT05696613","A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy",[38],"Phase 3","2026-08-26T02:14:59.425132Z","2026-05-05T02:43:27.998701Z",{"nct_id":42,"title":43,"phases":44,"status":12,"updated_at":45,"content_modified":46},"NCT06962800","A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)",[38],"2026-08-26T02:19:04.543908Z","2026-05-05T02:43:27.513583Z",{"nct_id":48,"title":49,"phases":50,"status":12,"updated_at":51,"content_modified":52},"NCT03949855","Belimumab With Rituximab for Primary Membranous Nephropathy",[11],"2026-08-26T02:15:00.557154Z","2026-04-29T02:57:57.088720Z",{"nct_id":54,"title":55,"phases":56,"status":12,"updated_at":58,"content_modified":59},"NCT06557265","A Phase 1\u002F2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)",[57],"Phase 1\u002FPhase 2","2026-08-26T02:18:58.958025Z","2026-06-17T02:29:30.003977Z",{"nct_id":61,"title":62,"phases":63,"status":12,"updated_at":64,"content_modified":65},"NCT06983028","Atacicept in Multiple Glomerular Diseases",[11],"2026-08-26T02:17:42.501124Z","2026-07-05T05:32:16.725563Z",[67],{"biomarker":68,"count":69,"slug":70},"Secretory Phospholipase A2 Receptor",6,"secretory-phospholipase-a2-receptor",[72,76,80,83,87,91,94,98,101,104],{"state":73,"count":74,"slug":75},"California",8,"california",{"state":77,"count":78,"slug":79},"New York",7,"new-york",{"state":81,"count":78,"slug":82},"Texas","texas",{"state":84,"count":85,"slug":86},"Florida",5,"florida",{"state":88,"count":89,"slug":90},"Georgia",4,"georgia",{"state":92,"count":89,"slug":93},"Michigan","michigan",{"state":95,"count":96,"slug":97},"Alabama",3,"alabama",{"state":99,"count":96,"slug":100},"Colorado","colorado",{"state":102,"count":96,"slug":103},"Illinois","illinois",{"state":105,"count":96,"slug":106},"Minnesota","minnesota"]